{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T15:37:15Z","timestamp":1793633835392,"version":"4.5.1"},"reference-count":224,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejmech.2025.118117","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T12:45:43Z","timestamp":1757335543000},"page":"118117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Small-molecule FGFR-targeted medicinal chemistry: Advances since 2020 and future perspectives"],"prefix":"10.1016","volume":"300","author":[{"given":"Hao","family":"Yue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialong","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlei","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118117_bib1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1006\/geno.2000.6332","article-title":"Characterization of a novel protein (FGFRL1) from human cartilage related to FGF receptors","volume":"69","author":"Wiedemann","year":"2000","journal-title":"Genomics"},{"key":"10.1016\/j.ejmech.2025.118117_bib2","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00018-010-0576-3","article-title":"Biology of FGFRL1, the fifth fibroblast growth factor receptor","volume":"68","author":"Trueb","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2025.118117_bib3","doi-asserted-by":"crossref","first-page":"15292","DOI":"10.1074\/jbc.271.25.15292","article-title":"Receptor specificity of the fibroblast growth factor family","volume":"271","author":"Ornitz","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd2792","article-title":"The FGF family: biology, pathophysiology and therapy","volume":"8","author":"Beenken","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118117_bib5","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.118117_bib6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/wdev.176","article-title":"The fibroblast growth factor signaling pathway","volume":"4","author":"Ornitz","year":"2015","journal-title":"Wiley Interdiscip. Rev. Dev. Biol."},{"key":"10.1016\/j.ejmech.2025.118117_bib7","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.118117_bib8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","article-title":"FGF\/FGFR signaling in health and disease","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2025.118117_bib9","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.tips.2016.10.003","article-title":"Therapeutics targeting FGF signaling network in human diseases","volume":"37","author":"Katoh","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2025.118117_bib10","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s10495-013-0886-7","article-title":"Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers","volume":"18","author":"Tiong","year":"2013","journal-title":"Apoptosis"},{"key":"10.1016\/j.ejmech.2025.118117_bib11","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41571-018-0115-y","article-title":"Fibroblast growth factor receptors as treatment targets in clinical oncology","volume":"16","author":"Katoh","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118117_bib12","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/1535-7163.MCT-11-0450","article-title":"Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models","volume":"11","author":"Gozgit","year":"2012","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.118117_bib13","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1124\/jpet.117.244129","article-title":"Triple angiokinase inhibitor nintedanib directly inhibits tumor cell growth and induces tumor shrinkage via blocking oncogenic receptor tyrosine kinases","volume":"364","author":"Hilberg","year":"2018","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2025.118117_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/ijmm.2016.2620","article-title":"FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)","volume":"38","author":"Katoh","year":"2016","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ejmech.2025.118117_bib15","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"BLC2001 study group, erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118117_bib16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"FOENIX-CCA2 study investigators, futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118117_bib17","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2025.118117_bib18","first-page":"803","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study, Lancet Gastroenterol","volume":"6","author":"Javle","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2025.118117_bib19","article-title":"Clinical development and management of adverse events associated with FGFR inhibitors","volume":"4","author":"Subbiah","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ejmech.2025.118117_bib20","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.3390\/cancers13122968","article-title":"FGFR inhibitors in oncology: insight on the management of toxicities in clinical practice","volume":"13","author":"Kommalapati","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2025.118117_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2022.12.019","article-title":"Management of fibroblast growth factor inhibitor treatment-emergent adverse events of interest in patients with locally advanced or metastatic urothelial carcinoma","volume":"50","author":"Siefker-Radtke","year":"2023","journal-title":"Eur. Urol. Open Sci."},{"key":"10.1016\/j.ejmech.2025.118117_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103091","article-title":"Prevention and treatment of FGFR inhibitor-associated toxicities","volume":"155","author":"Mahipal","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejmech.2025.118117_bib23","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ophtha.2020.08.026","article-title":"Ocular adverse effects of infigratinib, a new fibroblast growth factor receptor tyrosine kinase inhibitor","volume":"128","author":"Magone","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejmech.2025.118117_bib24","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","article-title":"FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions","volume":"21","author":"Katoh","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118117_bib25","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion\u2013positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2025.118117_bib26","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1021\/acschembio.5b00014","article-title":"Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy","volume":"10","author":"Sohl","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118117_bib27","doi-asserted-by":"crossref","first-page":"15694","DOI":"10.1074\/jbc.M601252200","article-title":"Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family","volume":"281","author":"Zhang","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib28","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s11684-019-0711-y","article-title":"The FGF metabolic axis","volume":"13","author":"Li","year":"2019","journal-title":"Front. Med."},{"key":"10.1016\/j.ejmech.2025.118117_bib29","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cytogfr.2005.01.001","article-title":"Cellular signaling by fibroblast growth factor receptors","volume":"16","author":"Eswarakumar","year":"2005","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ejmech.2025.118117_bib30","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/s41586-023-06155-9","article-title":"Structural basis for FGF hormone signalling","volume":"618","author":"Chen","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118117_bib31","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a004952","article-title":"Heparan sulfate proteoglycans","volume":"3","author":"Sarrazin","year":"2011","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.ejmech.2025.118117_bib32","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1097-2765(00)00073-3","article-title":"Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization","volume":"6","author":"Schlessinger","year":"2000","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2025.118117_bib33","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nrm3528","article-title":"Exploring mechanisms of FGF signalling through the lens of structural biology","volume":"14","author":"Goetz","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118117_bib34","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.21137","article-title":"Elucidation of a four-site allosteric network in fibroblast growth factor receptor tyrosine kinases","volume":"6","author":"Chen","year":"2017","journal-title":"eLife"},{"key":"10.1016\/j.ejmech.2025.118117_bib35","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.str.2019.05.002","article-title":"A conserved allosteric pathway in tyrosine kinase regulation","volume":"27","author":"Marsiglia","year":"2019","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2025.118117_bib36","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.3390\/cancers13225681","article-title":"Biological significance and targeting of the FGFR Axis in cancer","volume":"13","author":"Chioni","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2025.118117_bib37","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1128\/MCB.20.3.979-989.2000","article-title":"FRS2 proteins recruit intracellular signaling pathways by binding to diverse targets on fibroblast growth factor and nerve growth factor receptors","volume":"20","author":"Ong","year":"2000","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118117_bib38","doi-asserted-by":"crossref","first-page":"8578","DOI":"10.1073\/pnas.161259898","article-title":"Critical role for the docking-protein FRS2 alpha in FGF receptor-mediated signal transduction pathways","volume":"98","author":"Hadari","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2025.118117_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.3146re9","article-title":"Fibroblast growth factor receptor signaling cross-talk in skeletogenesis","volume":"3","author":"Miraoui","year":"2010","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ejmech.2025.118117_bib40","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1534-5807(02)00261-7","article-title":"Interaction of FGF, Ihh\/Pthlh, and BMP signaling integrates chondrocyte proliferation and hypertrophic differentiation","volume":"3","author":"Minina","year":"2002","journal-title":"Dev. Cell"},{"key":"10.1016\/j.ejmech.2025.118117_bib41","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.4161\/cbt.5.9.3151","article-title":"Cross-talk of WNT and FGF signaling pathways at GSK3beta to regulate beta-catenin and SNAIL signaling cascades","volume":"5","author":"Katoh","year":"2006","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ejmech.2025.118117_bib42","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.2353\/ajpath.2007.061111","article-title":"Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells","volume":"170","author":"Zhu","year":"2007","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejmech.2025.118117_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10262","article-title":"Mechanism of FGF receptor dimerization and activation","volume":"7","author":"Sarabipour","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118117_bib44","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/hep.23708","article-title":"Glycosylation of fibroblast growth factor receptor 4 is a key regulator of fibroblast growth factor 19-mediated down-regulation of cytochrome P450 7A1","volume":"52","author":"Triantis","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2025.118117_bib45","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12964-019-0371-1","article-title":"Differential regulation of fibroblast growth factor receptor 1 trafficking and function by extracellular galectins","volume":"17","author":"Kuci\u0144ska","year":"2019","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ejmech.2025.118117_bib46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/jcm8010007","article-title":"Targeting cellular trafficking of fibroblast growth factor receptors as a strategy for selective cancer treatment","volume":"8","author":"Por\u0119bska","year":"2018","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejmech.2025.118117_bib47","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.3390\/cells10092418","article-title":"The saga of endocrine FGFs","volume":"10","author":"Phan","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2025.118117_bib48","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s13105-019-00675-7","article-title":"FGF19 subfamily members: FGF19 and FGF21","volume":"75","author":"Dolegowska","year":"2019","journal-title":"J. Physiol. Biochem."},{"key":"10.1016\/j.ejmech.2025.118117_bib49","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00223-015-0013-6","article-title":"Biphasic effects of VitaminD and FGF23 on human osteoclast biology","volume":"97","author":"Allard","year":"2015","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.ejmech.2025.118117_bib50","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41571-018-0115-y","article-title":"Fibroblast growth factor receptors as treatment targets in clinical oncology","volume":"16","author":"Katoh","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118117_bib51","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118117_bib52","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e16549","article-title":"Clinicopathological characterization, FGFR alteration prevalence, and outcomes of locally advanced or metastatic urothelial cancer in Latin America (LACOG 1518)","volume":"40","author":"Souza","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118117_bib53","doi-asserted-by":"crossref","first-page":"490","DOI":"10.20892\/j.issn.2095-3941.2020.0120","article-title":"Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases","volume":"18","author":"Zhou","year":"2021","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.ejmech.2025.118117_bib54","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s00384-022-04162-2","article-title":"Prospective analysis of the expression status of FGFR2 and HER2 in colorectal and gastric cancer populations: DS-Screen Study, Int. J","volume":"37","author":"Yasui","year":"2022","journal-title":"Colorectal Dis."},{"key":"10.1016\/j.ejmech.2025.118117_bib55","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.21037\/atm-20-5118","article-title":"A comprehensive pancancer study of fibroblast growth factor receptor aberrations in Chinese cancer patients","volume":"8","author":"Sun","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ejmech.2025.118117_bib56","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1158\/1078-0432.CCR-18-3258","article-title":"Mutational diversity and therapy response in breast cancer: a sequencing analysis in the neoadjuvant GeparSepto trial","volume":"25","author":"Loibl","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118117_bib57","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-024-01558-1","article-title":"Targeting FGFR for cancer therapy","volume":"17","author":"Zhang","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118117_bib58","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00428-014-1634-2","article-title":"FGFR1 amplification is associated with poor prognosis and smoking in non-small-cell lung cancer","volume":"465","author":"Seo","year":"2014","journal-title":"Virchows Arch."},{"key":"10.1016\/j.ejmech.2025.118117_bib59","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-09-3746","article-title":"FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer","volume":"70","author":"Turner","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118117_bib60","first-page":"5055","article-title":"Amplification of FGFR2 gene in patients with advanced gastric cancer receiving chemotherapy: prevalence and prognostic significance","volume":"35","author":"Shoji","year":"2015","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejmech.2025.118117_bib61","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202100974","article-title":"Activation of FGFR2 signaling suppresses BRCA1 and drives triple-negative mammary tumorigenesis that is sensitive to immunotherapy","volume":"8","author":"Lei","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ejmech.2025.118117_bib62","article-title":"A pancancer analysis of the expression landscape and clinical relevance of fibroblast growth factor receptor 2 in human cancers","volume":"11","author":"Li","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2025.118117_bib63","doi-asserted-by":"crossref","first-page":"16541","DOI":"10.18632\/aging.203175","article-title":"Insights of fibroblast growth factor receptor 3 aberrations in pan-cancer and their roles in potential clinical treatment","volume":"13","author":"Li","year":"2021","journal-title":"Aging"},{"key":"10.1016\/j.ejmech.2025.118117_bib64","first-page":"3395","article-title":"Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models","volume":"119","author":"Taylor","year":"2009","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2025.118117_bib65","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.gde.2017.10.002","article-title":"Chimeric RNAs and their implications in cancer","volume":"48","author":"Li","year":"2018","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.ejmech.2025.118117_bib66","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.e13001","article-title":"Incidence of FGFR-TACC gene fusions in Chinese non-small cell lung cancer (NSCLC): a multicenter study","volume":"37","author":"Cai","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118117_bib67","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1038\/leu.2012.109","article-title":"RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation","volume":"26","author":"Ballerini","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.118117_bib68","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1002\/ijc.32665","article-title":"Critical individual roles of the BCR and FGFR1 kinase domains in BCR-FGFR1-driven stem cell leukemia\/lymphoma syndrome","volume":"146","author":"Chong","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.118117_bib69","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jhep.2021.02.032","article-title":"FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma","volume":"75","author":"Cristinziano","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2025.118117_bib70","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cytogfr.2019.12.005","article-title":"Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma","volume":"52","author":"Li","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ejmech.2025.118117_bib71","first-page":"1206","article-title":"Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas","volume":"19","author":"Granberg","year":"2017","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejmech.2025.118117_bib72","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2141.2004.04996.x","article-title":"Correlation of TACC3, FGFR3, MMSET and p21 expression with the t(4;14)(p16.3;q32) in multiple myeloma","volume":"126","author":"Stewart","year":"2004","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2025.118117_bib73","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1126\/science.1220834","article-title":"Transforming fusions of FGFR and TACC genes in human glioblastoma","volume":"337","author":"Singh","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118117_bib74","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1158\/1535-7163.MCT-14-0927-T","article-title":"Mechanism of oncogenic signal activation by the novel fusion kinase FGFR3-BAIAP2L1","volume":"14","author":"Nakanishi","year":"2015","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.118117_bib75","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.2741\/1671","article-title":"Roles of FGF signaling in skeletal development and human genetic diseases","volume":"10","author":"Chen","year":"2005","journal-title":"Front. Biosci."},{"key":"10.1016\/j.ejmech.2025.118117_bib76","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.gene.2013.09.120","article-title":"Increased FGF3 and FGF4 gene dosage is a risk factor for craniosynostosis","volume":"534","author":"Grillo","year":"2014","journal-title":"Gene"},{"key":"10.1016\/j.ejmech.2025.118117_bib77","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1172\/JCI34538","article-title":"Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice","volume":"118","author":"Falardeau","year":"2008","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2025.118117_bib78","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/humu.23292","article-title":"FGF9 mutation causes craniosynostosis along with multiple synostoses","volume":"38","author":"Rodriguez-Zabala","year":"2017","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ejmech.2025.118117_bib79","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/jmedgenet-2013-101659","article-title":"Whole exome sequencing identifies FGF16 nonsense mutations as the cause of X-linked recessive metacarpal 4\/5 fusion","volume":"50","author":"Tammesheer","year":"2013","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ejmech.2025.118117_bib80","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ajhg.2013.04.008","article-title":"Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism","volume":"92","author":"Miraoui","year":"2013","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ejmech.2025.118117_bib81","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/81664","article-title":"Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23","volume":"26","year":"2000","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2025.118117_bib82","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1210\/jc.2004-2238","article-title":"A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis","volume":"90","author":"Larsson","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2025.118117_bib83","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1086\/427956","article-title":"Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation","volume":"76","author":"White","year":"2005","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ejmech.2025.118117_bib84","doi-asserted-by":"crossref","first-page":"314","DOI":"10.2478\/v10039-012-0036-4","article-title":"Evidence that FGFR1 loss-of-function mutations may cause variable skeletal malformations in patients with Kallmann syndrome","volume":"57","author":"Jarzabek","year":"2012","journal-title":"Adv. Med. Sci."},{"key":"10.1016\/j.ejmech.2025.118117_bib85","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ajhg.2012.02.005","article-title":"Bent bone dysplasia-FGFR2 type, a distinct skeletal disorder, has deficient canonical FGF signaling","volume":"90","author":"Merrill","year":"2012","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ejmech.2025.118117_bib86","first-page":"297","article-title":"Rapid detection of G1138A and G1138C mutations of the FGFR3 gene in patients with achondroplasia using high-resolution melting analysis, Genet. Test","volume":"16","author":"He","year":"2012","journal-title":"Mol. Biomark."},{"key":"10.1016\/j.ejmech.2025.118117_bib87","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.mrrev.2013.11.001","article-title":"The paradox of FGFR3 signaling in skeletal dysplasia: why chondrocytes growth arrest while other cells over proliferate","volume":"759","author":"Krejci","year":"2014","journal-title":"Mutat. Res. Rev. Mutat. Res."},{"key":"10.1016\/j.ejmech.2025.118117_bib88","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1002\/ajmg.a.34199","article-title":"Mild isolated craniosynostosis due to a novel FGFR3 mutation","volume":"155A","author":"Barroso","year":"2011","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.ejmech.2025.118117_bib89","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/humu.22597","article-title":"A novel homozygous mutation in FGFR3 causes tall stature, severe lateral tibial deviation, scoliosis, hearing impairment, camptodactyly, and arachnodactyly","volume":"35","author":"Makrythanasis","year":"2014","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ejmech.2025.118117_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117275","article-title":"Current and emerging therapies for Achondroplasia: the dawn of precision medicine","volume":"87","author":"Dardenne","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib91","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/bs.ctdb.2018.11.020","article-title":"Fibroblast growth factors in skeletal development","volume":"133","author":"Ornitz","year":"2019","journal-title":"Curr. Top. Dev. Biol."},{"key":"10.1016\/j.ejmech.2025.118117_bib92","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1002\/ajmg.a.35642","article-title":"Neuroimaging and neurological findings in patients with hypochondroplasia and FGFR3 N540K mutation","volume":"A 158A","author":"Linnankivi","year":"2012","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.ejmech.2025.118117_bib93","first-page":"935","article-title":"Relationship between the gene polymorphism in fibroblast growth factor-10 and susceptibility to chronic obstructive pulmonary disease 220 cases","volume":"36","author":"Ren","year":"2013","journal-title":"Zhonghua Jiehe He Huxi Zazhi"},{"key":"10.1016\/j.ejmech.2025.118117_bib94","doi-asserted-by":"crossref","first-page":"E974","DOI":"10.1073\/pnas.1715564115","article-title":"MESA Lung and SPIROMICS investigators, Human airway branch variation and chronic obstructive pulmonary disease","volume":"115","author":"Smith","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2025.118117_bib95","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1155\/2013\/932356","article-title":"Association of a FGFR-4 gene polymorphism with bronchopulmonary dysplasia and neonatal respiratory distress","volume":"35","author":"Rezvani","year":"2013","journal-title":"Dis. Markers"},{"key":"10.1016\/j.ejmech.2025.118117_bib96","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/ng1757","article-title":"Mutations in different components of FGF signaling in LADD syndrome","volume":"38","author":"Rohmann","year":"2006","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2025.118117_bib97","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1399-0004.2005.00477.x","article-title":"Vertebral anomalies and cartilaginous tracheal sleeve in three patients with Pfeiffer syndrome carrying the S351C FGFR2 mutation","volume":"68","author":"Gonzales","year":"2005","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ejmech.2025.118117_bib98","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/humu.23032","article-title":"Ectrodactyly and lethal pulmonary acinar dysplasia associated with homozygous FGFR2 mutations identified by exome sequencing","volume":"37","author":"Barnett","year":"2016","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ejmech.2025.118117_bib99","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12931-015-0242-2","article-title":"Increased FGF1-FGFRc expression in idiopathic pulmonary fibrosis","volume":"16","author":"MacKenzie","year":"2015","journal-title":"Respir. Res."},{"key":"10.1016\/j.ejmech.2025.118117_bib100","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/jcmm.14793","article-title":"A new FGFR inhibitor disrupts the TGF-\u03b21-induced fibrotic process","volume":"24","author":"Kim","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejmech.2025.118117_bib101","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13081","article-title":"A novel multikinase inhibitor SKLB-YTH-60 ameliorates inflammation and fibrosis in bleomycin-induced lung fibrosis mouse models","volume":"54","author":"Liu","year":"2021","journal-title":"Cell Prolif."},{"key":"10.1016\/j.ejmech.2025.118117_bib102","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1073\/pnas.1200797109","article-title":"Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor gamma","volume":"109","author":"Wei","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2025.118117_bib103","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.2337\/db14-0541","article-title":"FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting","volume":"63","author":"Liang","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.ejmech.2025.118117_bib104","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/jbmr.485","article-title":"The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat","volume":"26","author":"Moe","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.ejmech.2025.118117_bib105","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-50669-0","article-title":"FGFR4 does not contribute to progression of chronic kidney disease","volume":"9","author":"Taylor","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118117_bib106","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.kint.2025.01.024","article-title":"Fibroblast growth factor 23 and fibroblast growth factor receptor 4 promote cardiac metabolic remodeling in chronic kidney disease","volume":"107","author":"Fuchs","year":"2025","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejmech.2025.118117_bib107","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jhep.2017.01.027","article-title":"Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19\/FGF15","volume":"66","author":"Zhou","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2025.118117_bib108","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","article-title":"The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic","volume":"16","author":"Geng","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.ejmech.2025.118117_bib109","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.83075","article-title":"FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis","volume":"12","author":"Liu","year":"2023","journal-title":"eLife"},{"key":"10.1016\/j.ejmech.2025.118117_bib110","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.canlet.2020.11.026","article-title":"FGF21 in obesity and cancer: new insights","volume":"499","author":"Lu","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2025.118117_bib111","doi-asserted-by":"crossref","first-page":"9923","DOI":"10.7150\/thno.45988","article-title":"Lack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling","volume":"10","author":"Zheng","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2025.118117_bib112","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/emmm.201303716","article-title":"FGF23 regulates renal sodium handling and blood pressure","volume":"6","author":"Andrukhova","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ejmech.2025.118117_bib113","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.bone.2012.05.015","article-title":"FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1\/2-SGK1 signaling pathway","volume":"51","author":"Andrukhova","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.ejmech.2025.118117_bib114","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1242\/jcs.112.12.2049","article-title":"Keratinocyte growth factor induces angiogenesis and protects endothelial barrier function","volume":"112","author":"Gillis","year":"1999","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ejmech.2025.118117_bib115","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.4049\/jimmunol.1400562","article-title":"Temporal expression of growth factors triggered by epiregulin regulates inflammation development","volume":"194","author":"Harada","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2025.118117_bib116","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.ijporl.2011.07.026","article-title":"Tissue remodeling in the acute otitis media mouse model","volume":"75","author":"Sautter","year":"2011","journal-title":"Int. J. Pediatr. Otorhinolaryngol."},{"key":"10.1016\/j.ejmech.2025.118117_bib117","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1210\/en.2011-1496","article-title":"FGF21 is increased by inflammatory stimuli and protects leptin-deficient ob\/ob mice from the toxicity of sepsis","volume":"153","author":"Feingold","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejmech.2025.118117_bib118","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3390\/cells8060614","article-title":"Fibroblast growth factor receptors (FGFRs): structures and small molecule inhibitors","volume":"8","author":"Dai","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2025.118117_bib119","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/ijc.32224","article-title":"Rogaratinib: a potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models","volume":"145","author":"Gr\u00fcnewald","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.118117_bib120","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1158\/1535-7163.MCT-11-0306","article-title":"A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models","volume":"10","author":"Zhao","year":"2011","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.118117_bib121","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1158\/0008-5472.CAN-11-3034","article-title":"AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family","volume":"72","author":"Gavine","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118117_bib122","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1158\/1535-7163.MCT-14-0248","article-title":"The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284\/Debio 1347, a novel selective FGFR inhibitor","volume":"13","author":"Nakanishi","year":"2014","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.118117_bib123","doi-asserted-by":"crossref","first-page":"16737","DOI":"10.1021\/acs.jmedchem.4c01531","article-title":"Discovery of TYRA-300: first oral selective FGFR3 inhibitor for the treatment of urothelial cancers and achondroplasia","volume":"67","author":"Hudkins","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib124","doi-asserted-by":"crossref","first-page":"12542","DOI":"10.1021\/acs.jmedchem.0c01019","article-title":"Discovery of roblitinib (FGF401) as a reversible-covalent inhibitor of the kinase activity of fibroblast growth factor receptor 4","volume":"63","author":"Fairhurst","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib125","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1158\/2159-8290.CD-14-1029","article-title":"First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway","volume":"5","author":"Hagel","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2025.118117_bib126","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-12-0362","article-title":"Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives","volume":"3","author":"Dieci","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2025.118117_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115764","article-title":"Design, synthesis and evaluation of novel pyrimidinylaminothiophene derivatives as FGFR1 inhibitors against human glioblastoma multiforme","volume":"260","author":"Li","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107553","article-title":"Discovery and characterization of novel FGFR1 inhibitors in triple-negative breast cancer via hybrid virtual screening and molecular dynamics simulations","volume":"150","author":"Wang","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115006","article-title":"Prenylated flavonoids with significant anti-hepatoma activity from Daphne giraldii and effects on Fibroblast Growth Factor Receptor 1 (FGFR1)","volume":"247","author":"Liu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102170","article-title":"Targeting FGFR inhibition in cholangiocarcinoma","volume":"95","author":"Goyal","year":"2021","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2025.118117_bib131","first-page":"3893","article-title":"Comprehensive identification of FGFR1-4 alterations in 5 557 Chinese patients with solid tumors by next-generation sequencing","volume":"11","author":"Gu","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118117_bib132","first-page":"803","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study, Lancet Gastroenterol","volume":"6","author":"Javle","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2025.118117_bib133","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118117_bib134","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.3390\/cancers13122968","article-title":"FGFR inhibitors in oncology: insight on the management of toxicities in clinical practice","volume":"13","author":"Kommalapati","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.118117_bib135","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/2159-8290.CD-23-0475","article-title":"RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations","volume":"13","author":"Subbiah","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2025.118117_bib136","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2317756121","article-title":"Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2","volume":"121","author":"Sch\u00f6nherr","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2025.118117_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116473","article-title":"Discovery of LHQ490 as a highly selective fibroblast growth factor receptor 2 (FGFR2) inhibitor","volume":"272","author":"Li","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117339","article-title":"Discovery of BW710 as a potent, selective and orally bioavailable fibroblast growth factor receptor 2 (FGFR2) inhibitor","volume":"287","author":"Yang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib139","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1021\/acs.jmedchem.1c01163","article-title":"From fragment to lead: de novo design and development toward a selective FGFR2 inhibitor","volume":"65","author":"Turner","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib140","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"BLC2001 study group, erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118117_bib141","doi-asserted-by":"crossref","first-page":"23935","DOI":"10.1074\/jbc.M115.672410","article-title":"Characterization of the catalytic and nucleotide binding properties of the alpha-kinase domain of dictyostelium myosin-II heavy chain kinase A","volume":"290","author":"Yang","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib142","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1007\/s10620-013-2609-x","article-title":"Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma","volume":"58","author":"Hyeon","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejmech.2025.118117_bib143","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1007\/s13277-013-1374-y","article-title":"High fibroblast growth factor 19 (FGF19) expression predicts worse prognosis in invasive ductal carcinoma of breast","volume":"35","author":"Buhmeida","year":"2014","journal-title":"Tumor Biol."},{"key":"10.1016\/j.ejmech.2025.118117_bib144","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036713","article-title":"Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models","volume":"7","author":"French","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.118117_bib145","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1158\/2159-8290.CD-14-1029","article-title":"First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway","volume":"5","author":"Hagel","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2025.118117_bib146","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1021\/acsmedchemlett.9b00601","article-title":"Discovery of selective, covalent FGFR4 inhibitors with antitumor activity in models of hepatocellular carcinoma","volume":"11","author":"Liu","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118117_bib147","doi-asserted-by":"crossref","first-page":"7595","DOI":"10.1021\/acs.jmedchem.1c01977","article-title":"Discovery of 1,6-naphthyridin-2(1H)-one derivatives as novel, potent, and selective FGFR4 inhibitors for the treatment of hepatocellular carcinoma","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115703","article-title":"Design, synthesis, and biological evaluation of 1,6-naphthyridine-2-one derivatives as novel FGFR4 inhibitors for the treatment of colorectal cancer","volume":"259","author":"Fang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib149","doi-asserted-by":"crossref","first-page":"8445","DOI":"10.1021\/acs.jmedchem.4c00758","article-title":"Discovery of 2,6-naphthyridine analogues as selective FGFR4 inhibitors for hepatocellular carcinoma","volume":"67","author":"Oh","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115862","article-title":"Pyrrolo[2,3-b]pyridine-3-one derivatives as novel fibroblast growth factor receptor 4 inhibitors for the treatment of hepatocellular carcinoma","volume":"29","author":"Jin","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib151","doi-asserted-by":"crossref","first-page":"7278","DOI":"10.1021\/acs.jmedchem.2c00255","article-title":"Discovery of novel 7-azaindole derivatives as selective covalent fibroblast growth factor receptor 4 inhibitors for the treatment of hepatocellular carcinoma","volume":"65","author":"Zhong","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113794","article-title":"Design, synthesis and biological evaluation of quinazoline derivatives as potent and selective FGFR4 inhibitors","volume":"225","author":"Pan","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib153","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1016\/j.bmcl.2017.04.014","article-title":"Discovery and optimization of selective FGFR4 inhibitors via scaffold hopping","volume":"27","author":"Wang","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118117_bib154","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1021\/acs.jmedchem.3c02483","article-title":"Development of highly potent and selective covalent FGFR4 inhibitors based on SNAr electrophiles","volume":"67","author":"Schwarz","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib155","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1021\/acs.jmedchem.8b01153","article-title":"Emerging and Re-emerging warheads for targeted covalent inhibitors: applications in medicinal chemistry and chemical biology","volume":"62","author":"Gehringer","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib156","doi-asserted-by":"crossref","first-page":"7668","DOI":"10.1021\/acs.jmedchem.3c01825","article-title":"Emerging and Re-emerging warheads for targeted covalent inhibitors: an update","volume":"67","author":"Hillebrand","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105673","article-title":"Design, synthesis, and biological evaluation of quinazoline derivatives with covalent reversible warheads as potential FGFR4 inhibitors","volume":"121","author":"Nie","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib158","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nchembio.1813","article-title":"Know your target, know your molecule","volume":"11","author":"Bunnage","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118117_bib159","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1021\/jm3003203","article-title":"Irreversible protein kinase inhibitors: balancing the benefits and risks","volume":"55","author":"Barf","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib160","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.drudis.2015.05.005","article-title":"Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies","volume":"20","author":"Bauer","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2025.118117_bib161","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/tx700186p","article-title":"Idiosyncratic drug reactions: past, present, and future","volume":"21","author":"Uetrecht","year":"2008","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2025.118117_bib162","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1021\/tx5001046","article-title":"Molecular mechanisms of aldehyde toxicity: a chemical perspective","volume":"27","author":"LoPachin","year":"2014","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2025.118117_bib163","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1021\/acs.jmedchem.1c01816","article-title":"Design, synthesis, and biological evaluation of 2-formyl tetrahydronaphthyridine urea derivatives as new selective covalently reversible FGFR4 inhibitors","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib164","doi-asserted-by":"crossref","first-page":"14809","DOI":"10.1021\/acs.jmedchem.2c01319","article-title":"Design, synthesis, and biological evaluation of 5-Formyl-pyrrolo[3,2-b]pyridine-3-carboxamides as new selective, potent, and reversible-covalent FGFR4 inhibitors","volume":"65","author":"Yang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib165","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1021\/acs.jmedchem.3c01810","article-title":"Discovery of 6-formylpyridyl urea derivatives as potent reversible-covalent fibroblast growth factor receptor 4 inhibitors with improved anti-hepatocellular carcinoma activity","volume":"67","author":"Yang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib166","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-021-01040-2","article-title":"FGFR-TKI resistance in cancer: current status and perspectives","volume":"14","author":"Yue","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118117_bib167","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1158\/2159-8290.CD-19-0367","article-title":"Acquired ontarget clinical resistance validates FGFR4 as a driver of hepatocellular carcinoma","volume":"9","author":"Hatlen","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2025.118117_bib168","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1021\/acs.jmedchem.2c00096","article-title":"Design, synthesis, and biological evaluation of aminoindazole derivatives as highly selective covalent inhibitors of wild-type and gatekeeper mutant FGFR4","volume":"65","author":"Shao","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib169","doi-asserted-by":"crossref","first-page":"12089","DOI":"10.1039\/C8CC07546H","article-title":"LY2874455 potently inhibits FGFR gatekeeper mutants and overcomes mutation-based resistance","volume":"54","author":"Wu","year":"2018","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2025.118117_bib170","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108469","article-title":"Optimization of Aminoindazole derivatives as highly selective covalent inhibitors for wild-type and mutant FGFR4","volume":"160","author":"Guo","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115628","article-title":"Design, synthesis and biological evaluation of indazole derivatives as selective covalent inhibitors of FGFR4 in wild-type and gatekeeper mutants","volume":"258","author":"Yang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib172","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s42004-022-00657-9","article-title":"Structure - based design of a dual - warhead covalent inhibitor of FGFR4","volume":"5","author":"Chen","year":"2022","journal-title":"Commun. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib173","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116281","article-title":"Design, synthesis, and biological evaluation of selective covalent inhibitors of FGFR4","volume":"268","author":"Chen","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib174","doi-asserted-by":"crossref","first-page":"11484","DOI":"10.1021\/acs.jmedchem.0c00044","article-title":"Development of a potent and specific FGFR4 inhibitor for the treatment of hepatocellular carcinoma","volume":"63","author":"Rezende","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117298","article-title":"Design, synthesis, and anticancer evaluation of arylurea derivatives as potent and selective type II irreversible covalent FGFR4 inhibitors","volume":"87","author":"Wang","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib176","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117206","article-title":"Design, synthesis, and biological evaluation of Ponatinib-based N-Phenylpyrimidine-2-amine derivatives as novel fibroblast growth factor receptor 4 (FGFR4) selective inhibitors","volume":"284","author":"Han","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib177","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113219","article-title":"Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer","volume":"214","author":"Chen","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib178","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2024.2343350","article-title":"Discovery of novel FGFR4 inhibitors through a build-up fragment strategy","volume":"39","author":"Kim","year":"2024","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib179","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1080\/14756366.2022.2048378","article-title":"6-Amino-2,4,5-trimethylpyridin-3-ol and 2-amino-4,6-dimethylpyrimidin-5-ol derivatives as selective fibroblast growth factor receptor 4 inhibitors: design, synthesis, molecular docking, and anti-hepatocellular carcinoma efficacy evaluation","volume":"37","author":"Chaudhary","year":"2022","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib180","doi-asserted-by":"crossref","first-page":"15433","DOI":"10.1021\/acs.jmedchem.2c01366","article-title":"Discovery of potent and selective inhibitors of wild-type and gatekeeper mutant fibroblast growth factor receptor (FGFR) 2\/3","volume":"65","author":"Shvartsbart","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib181","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1021\/acsmedchemlett.0c00517","article-title":"Discovery of aminopyrazole derivatives as potent inhibitors of wild-type and gatekeeper mutant FGFR2 and 3","volume":"12","author":"Brawn","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118117_bib182","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1021\/acsmedchemlett.3c00003","article-title":"Discovery of orally bioavailable FGFR2\/FGFR3 dual inhibitors via structure-guided scaffold repurposing approach","volume":"14","author":"Nguyen","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118117_bib183","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1021\/acsmedchemlett.5c00232","article-title":"Discovery of INCB126503 as a potent and selective FGFR2\/3 inhibitor","volume":"16","author":"Nguyen","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118117_bib184","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1021\/acs.jmedchem.4c03205","article-title":"Discovery of pyrrolopyrazine carboxamide derivatives as potent and selective FGFR2\/3 inhibitors that overcome mutant resistance","volume":"68","author":"Wang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib185","doi-asserted-by":"crossref","first-page":"13887","DOI":"10.1021\/acs.jmedchem.5c00928","article-title":"Rational design and identification of ISM7594 as a tissue-agnostic FGFR2\/3 inhibitor","volume":"68","author":"Wang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib186","doi-asserted-by":"crossref","first-page":"7473","DOI":"10.1021\/acs.jmedchem.9b00510","article-title":"Discovery and development of a series of pyrazolo[3,4-d]pyridazinone compounds as the novel covalent fibroblast growth factor receptor inhibitors by the rational drug design","volume":"62","author":"Wang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib187","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.apsb.2020.09.002","article-title":"Design, synthesis and biological evaluation of pyrazolo[3,4-d]pyridazinone derivatives as covalent FGFR inhibitors","volume":"11","author":"Wu","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.118117_bib188","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1021\/acs.jmedchem.2c01507","article-title":"Structural optimization of fibroblast growth factor receptor inhibitors for treating solid tumors","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib189","doi-asserted-by":"crossref","first-page":"10666","DOI":"10.1021\/acs.jmedchem.1c00713","article-title":"Discovery of pemigatinib: a potent and selective fibroblast growth factor receptor (FGFR) inhibitor","volume":"64","author":"Wu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib190","doi-asserted-by":"crossref","first-page":"9078","DOI":"10.1021\/acs.jmedchem.1c00174","article-title":"Discovery and optimization of a novel 2H-Pyrazolo[3,4-d]pyrimidine derivative as a potent irreversible pan-fibroblast growth factor receptor inhibitor","volume":"64","author":"Wei","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib191","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112990","article-title":"Discovery and optimization of novel pyrazole - benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1\u20133)","volume":"210","author":"Yamani","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib192","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.1021\/acs.jmedchem.5c00124","article-title":"Discovery of novel 2,4,5-trisubstituted pyrimidine derivatives as potent and selective FGFR inhibitors against gatekeeper mutants for the treatment of NSCLC","volume":"68","author":"Zhang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib193","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117232","article-title":"Design, synthesis, and biological evaluation of a potent and orally bioavailable FGFRs inhibitor for fibrotic treatment","volume":"285","author":"Yue","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib194","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117047","article-title":"Structure-activity relationship studies of Imidazo[1',2':1,6]pyrido[2,3-d]pyrimidine derivatives to develop selective FGFR inhibitors as anticancer agents for FGF19-overexpressed hepatocellular carcinoma","volume":"282","author":"Kim","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib195","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1021\/acsmedchemlett.3c00006","article-title":"Discovery of futibatinib: the first covalent FGFR kinase inhibitor in clinical Use","volume":"14","author":"Ito","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118117_bib196","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115453","article-title":"Structure - based drug design of 1,3,5 - triazine and pyrimidine derivatives as novel FGFR3 inhibitors with high selectivity over VEGFR2","volume":"28","author":"Kuriwaki","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib197","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116019","article-title":"Synthesis and structure - activity relationships of pyrimidine derivatives as potent and orally active FGFR3 inhibitors with both increased systemic exposure and enhanced in vitro potency","volume":"33","author":"Kuriwaki","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib198","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116657","article-title":"Discovery of ASP5878: synthesis and structure - activity relationships of pyrimidine derivatives as pan - FGFRs inhibitors with improved metabolic stability and suppressed hERG channel inhibitory activity","volume":"59","author":"Kuriwaki","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib199","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1021\/acs.jmedchem.3c01819","article-title":"Discovery of KIN-3248, an irreversible, next generation FGFR inhibitor for the treatment of advanced tumors harboring FGFR2 and\/or FGFR3 gene alterations","volume":"67","author":"Tyhonas","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113499","article-title":"Design, synthesis and biological evaluations of a series of Pyrido[1,2-a]pyrimidinone derivatives as novel selective FGFR inhibitors","volume":"220","author":"Ran","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib201","doi-asserted-by":"crossref","first-page":"16570","DOI":"10.1021\/acs.jmedchem.2c01420","article-title":"Discovery of 2-Amino-7-sulfonyl-7H-pyrrolo[2,3-d]pyrimidine derivatives as potent reversible FGFR inhibitors with gatekeeper mutation tolerance: design, synthesis, and biological evaluation","volume":"65","author":"Xie","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib202","doi-asserted-by":"crossref","first-page":"6017","DOI":"10.1021\/acs.jmedchem.1c01776","article-title":"Identification of Pyridinyltriazine derivatives as potent panFGFR inhibitors against gatekeeper mutants for overcoming drug resistance","volume":"65","author":"Ryu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib203","doi-asserted-by":"crossref","first-page":"8858","DOI":"10.1021\/acs.jmedchem.3c00455","article-title":"Discovery and structural optimization of novel quinolone derivatives as potent irreversible pan-fibroblast growth factor receptor inhibitors for treating solid tumors","volume":"66","author":"Hu","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib204","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116558","article-title":"Design, synthesis and biological evaluation of 5-amino-1H-pyrazole-4-carboxamide derivatives as pan-FGFR covalent inhibitors","volume":"275","author":"Deng","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib205","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1021\/acsmedchemlett.4c00431","article-title":"Design, synthesis, and biological evaluation of 3-Amino-pyrazine-2-carboxamide derivatives as novel FGFR inhibitors","volume":"15","author":"Zheng","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118117_bib206","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116415","article-title":"Discovery of N-(4-((6-(3,5-Dimethoxyphenyl)-9H-purine derivatives as irreversible covalent FGFR inhibitors","volume":"271","author":"Wang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib207","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1021\/acs.jmedchem.3c02040","article-title":"Identification of Piperazinyl-difluoro-indene derivatives containing pyridyl groups as potent FGFR inhibitors against FGFR mutant tumor: design, synthesis, and biological evaluation","volume":"67","author":"Ding","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib208","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1158\/2159-8290.CD-23-0361","article-title":"SHP2 inhibition Sensitizes diverse oncogene-addicted solid tumors to Re-treatment with targeted therapy","volume":"13","author":"Drilon","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2025.118117_bib209","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1002\/ijc.32665","article-title":"Critical individual roles of the BCR and FGFR1 kinase domains in BCR-FGFR1-driven stem cell leukemia\/lymphoma syndrome","volume":"146","author":"Chong","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.118117_bib210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117745","article-title":"Discovery of LC-SF-14, a selective dual inhibitor of SHP2 and FGFR for the treatment of FGFR2-driven gastric cancer","volume":"294","author":"Zheng","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib211","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ccell.2016.08.001","article-title":"Feedback activation of leukemia inhibitory factor receptor limits response to histone deacetylase inhibitors in breast cancer","volume":"30","author":"Zeng","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2025.118117_bib212","first-page":"627","article-title":"FGFR inhibitor BGJ398 and HDAC inhibitor OBP-801 synergistically inhibit cell growth and induce apoptosis in bladder cancer cells","volume":"39","author":"Takamura","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejmech.2025.118117_bib213","doi-asserted-by":"crossref","first-page":"16541","DOI":"10.1021\/acs.jmedchem.2c01413","article-title":"Design and synthesis of fibroblast growth factor receptor (FGFR) and histone deacetylase (HDAC) dual inhibitors for the treatment of cancer","volume":"65","author":"Wan","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib214","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116096","article-title":"Progress in the controllability technology of PROTAC","volume":"265","author":"He","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib215","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3390\/ph17010100","article-title":"From PROTAC to TPD: advances and opportunities in targeted protein degradation","volume":"17","author":"Wang","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.118117_bib216","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.129864","article-title":"PROTAC-biomacromolecule conjugates for precise protein degradation in cancer therapy: a review","volume":"261","author":"Wang","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejmech.2025.118117_bib217","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116168","article-title":"Potential of the nanoplatform and PROTAC interface to achieve targeted protein degradation through the Ubiquitin-Proteasome system","volume":"267","author":"Xie","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib218","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.108109","article-title":"Design, synthesis, and biological evaluation of novel FGFR1 PROTACs","volume":"155","author":"Wang","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib219","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128982","article-title":"Development of selective FGFR1 degraders using a Rapid synthesis of proteolysis targeting Chimera (Rapid-TAC) platform","volume":"75","author":"Guo","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118117_bib220","doi-asserted-by":"crossref","first-page":"7438","DOI":"10.1021\/acs.jmedchem.3c00150","article-title":"Discovery of a selective and orally bioavailable FGFR2 degrader for treating gastric cancer","volume":"66","author":"Ma","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib221","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116612","article-title":"Design, synthesis and antitumor activity of a novel FGFR2-selective degrader to overcome resistance of the FGFR2V564F gatekeeper mutation based on a pan-FGFR inhibitor","volume":"275","author":"Hu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib222","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116780","article-title":"Synthesis and identification of a selective FGFR2 degrader with potent antiproliferative effects in gastric cancer","volume":"277","author":"Feng","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib223","doi-asserted-by":"crossref","first-page":"13858","DOI":"10.1021\/acs.jmedchem.5c00731","article-title":"LC-MF-4, a novel FGFR3 degrader for therapeutic intervention in FGFR3-altered cancers","volume":"68","author":"Zheng","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118117_bib224","doi-asserted-by":"crossref","first-page":"15905","DOI":"10.1002\/anie.202101328","article-title":"Discovery of a potent degrader for fibroblast growth factor receptor 1\/2","volume":"60","author":"Du","year":"2021","journal-title":"Angew. Chem. Int. Ed."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425008827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425008827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T15:19:06Z","timestamp":1760023146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425008827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":224,"alternative-id":["S0223523425008827"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118117","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small-molecule FGFR-targeted medicinal chemistry: Advances since 2020 and future perspectives","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118117","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118117"}}